with an average follow-up of 20.7 +/- 2.6 months with oral doses adapted to body weight and to the response to iv flecainide only one recurrence of atrial fibrillation was observed , a 100 % prevention of spontaneous svt and 94 % prevention of all arrhythmias ( 16 out of 17 cases ) .
C0016229
flecainide
C0003811
arrhythmias